Insider Trading March 30, 2026

Neuronetics Insider Purchases 385,442 Shares as Company Reports Mixed Q4 Results

Ten percent owner Jorey Chernett increases stake amid recent stock weakness; company posts revenue beat but EPS miss and names new CEO

By Marcus Reed STIM
Neuronetics Insider Purchases 385,442 Shares as Company Reports Mixed Q4 Results
STIM

Jorey Chernett, listed as a 10% owner of Neuronetics, Inc. (NASDAQ: STIM), bought 385,442 shares of common stock on March 30, 2026, according to a Form 4 filing. The purchases, executed at prices between $1.23 and $1.26, totaled $481,802 at an average price of $1.25 per share. The move comes as the stock trades near $1.27 and close to its 52-week low. Separately, Neuronetics reported fourth-quarter 2025 results that showed revenue above expectations but an EPS shortfall, announced a new CEO, and noted a quarter that was operationally cash flow positive.

Key Points

  • Jorey Chernett, a 10% owner, purchased 385,442 Neuronetics shares on March 30, 2026, at prices between $1.23 and $1.26, totaling $481,802 at an average of $1.25 per share.
  • Post-transaction, Chernett directly holds 9,778,988 shares; the stock traded at $1.27 at filing, near a 52-week low of $0.80 and following a 21% decline over the prior week.
  • Neuronetics reported Q4 2025 revenue of $41.8 million (2.73% above expectations) but missed EPS estimates with -$0.10 versus an expected -$0.09; the company named Dan Reuvers as CEO and reported a second quarter that was operationally cash flow positive.

Jorey Chernett, identified on filings as a 10% owner of Neuronetics, Inc. (NASDAQ: STIM), purchased 385,442 common shares on March 30, 2026, records show. The purchases were completed across multiple trades with prices spanning $1.23 to $1.26 per share, and the total reported value of the acquisition was $481,802, using an average price of $1.25 per share.

Following the transaction, Chernett's direct ownership in Neuronetics stands at 9,778,988 shares. At the time of the filing, the stock was trading at $1.27, which is close to its 52-week low of $0.80 and follows a 21% decline over the previous week.

Market valuation context from InvestingPro noted that the shares trade near a Fair Value estimate of $1.28. The filing and market snapshot were disclosed alongside the company’s recently reported fourth-quarter 2025 financial results, which presented a mixed picture for investors.

Neuronetics reported fourth-quarter revenue of $41.8 million, surpassing the consensus forecast of $40.66 million and representing a 2.73% positive surprise versus expectations. The company’s earnings per share, however, came in at -$0.10, below the anticipated -$0.09, an 11.11% negative surprise on EPS.

In addition to those figures, Neuronetics announced a leadership change, naming Dan Reuvers as its new chief executive officer. Management also reported that the company achieved a second quarter that was operationally cash flow positive.

On the analyst front, Canaccord revised its price target for Neuronetics downward from $7.00 to $3.00 while retaining a Buy rating on the shares. The firm indicated that the fourth-quarter results and the company’s guidance were in line with its expectations.

This insider purchase, taken together with the quarter’s financial details and the change in executive leadership, presents a set of data points for investors monitoring Neuronetics. The filing documents, reported pricing on the trades, ownership tally after the purchase, and the company’s most recent quarter results form the factual basis for assessing the current state of the company as presented in public disclosures.

Risks

  • Earnings risk - The company missed EPS expectations in Q4 2025, indicating near-term profitability challenges that could affect investor sentiment and valuations.
  • Market volatility risk - The stock has recently traded near its 52-week low and experienced a 21% decline over the prior week, reflecting potential volatility in shareholder value.
  • Analyst target risk - Canaccord lowered its price target from $7.00 to $3.00, signaling differing views on upside potential that may influence market expectations.

More from Insider Trading

Impact Biomedical CFO Disposes $25,330 in IBO Shares Across Two Trades Mar 30, 2026 Control Empresarial trims Talos Energy stake with $38.54 million share sale Mar 30, 2026 Advanced Flower Capital Director Increases Stake with $62,475 Purchase Mar 30, 2026 PBF Energy SVP Sells $2.57M in Stock After Exercising Long‑standing Options Mar 30, 2026 22NW Entities Trim Stake in L.B. Foster; Sale Coincides With Mixed Q4 2025 Results Mar 30, 2026